Soiken Holdings Inc. | Income Statement

Fiscal year is July-June. All values JPY Millions.
2014
2015
2016
2017
2018
Sales/Revenue
2,343
2,549
3,213
4,148
5,455
Cost of Goods Sold (COGS) incl. D&A
961
1,105
1,351
1,704
2,333
Gross Income
1,382
1,444
1,862
2,444
3,122
SG&A Expense
1,354
1,453
1,669
2,149
2,797
EBIT
28
10
183
264
326
Unusual Expense
-
1
20
-
3
Non Operating Income/Expense
1
1
1
1
3
Interest Expense
-
-
-
-
-
Pretax Income
37
6
171
272
332
Income Tax
17
13
96
85
126
Consolidated Net Income
20
6
76
187
206
Net Income
26
6
47
187
198
Net Income After Extraordinaries
26
6
47
187
198
Net Income Available to Common
26
6
47
187
198
EPS (Basic)
0.99
0.21
1.79
7.13
7.57
Basic Shares Outstanding
26
26
26
26
26
EPS (Diluted)
0.99
0.21
1.79
7.13
7.57
Diluted Shares Outstanding
26
26
26
26
26
EBITDA
46
7
198
285
357
Other Operating Expense
-
-
11
31
-
Non-Operating Interest Income
9
16
9
7
7
Minority Interest Expense
6
1
29
-
8

About Soiken Holdings

View Profile
Address
Senri Life Science Center, 13/F
Osaka Osaka 560
Japan
Employees -
Website http://www.soiken.com
Updated 07/08/2019
Soiken Holdings Inc. engages in the development of biomarkers and assessment systems. Its operates through the following segments: Biological Evaluation System, Health Care Support, Cosmetics, Marketing, Health Supplement and Functional materials. The Biological Evaluation System segment performs clinical evaluation tests on the function and safety of food.